Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

61 patients, male and female, with uncomplicated acute gonorrhea were given a single dose of 300 mg rosoxacin (2 capsules). 52 patients only completed clinical and laboratory controls. The drop-out rate for follow-up examinations was 14.8%. 98% of patients were cured. One patient failed to respond to treatment, and six had reinfection seven days later at follow-up control. Three of these were again treated with rosoxacin and cured. Among the side-effects, which were recorded in 24.4% of patients, dizziness was most prevalent (18.1%). Rosoxacin is particularly valuable in gonorrhea, given the single oral dose, the absence of resistance and the high percentage of efficacy.
 ...
PMID:[Efficacy and tolerability of single-dose rosoxacin in the treatment of acute uncomplicated gonorrhea]. 629 15

Rosoxacin, a beta-lactamase-resistant, pyridyl quinolone derivative with in vitro activity against Neisseria gonorrhoeae, was compared to an oral regimen of ampicillin plus probenecid for the treatment of uncomplicated gonococcal infection. Fifty-seven patients were evaluated for the effectiveness of the two antibiotics. Thirty (97%) of 31 patients receiving rosoxacin were cured of their infection as were 25 (96%) of 26 patients who received the oral regimen of ampicillin plus probenecid. Both drug regimens were associated with a significant number of side effects. Of the ampicillin-treated group, 29% had diarrhea and/or abdominal cramping. Of the rosoxacin-treated patients, 52% had reactions classified as central nervous system effects; these included headaches, dizziness, euphoria, and drowsiness.
 ...
PMID:A comparison of rosoxacin with ampicillin and probenecid in the treatment of uncomplicated gonorrhea. 671 Feb 84

In a randomized, double-blind, dose-ranging study, single oral doses of rosoxacin were used to treat 126 patients with uncomplicated genital or anorectal gonorrhea. Neisseria gonorrhoeae was eradicated from 5 (28%) of 18 men treated with 100 mg, compared with 101 (94%) of 108 men and women treated with 200 mg, 300 mg, or 400 mg (P less than 0.001). Susceptibility to rosoxacin was determined for 6 pretreatment gonococcal isolates from these patients and for 194 stored clinical isolates; 296 (98.7%) of these 300 isolates, including 10 strains of penicillinase-producing N. gonorrhaeae, required a minimal inhibitory concentration of less than or equal to 0.062 microgram/ml. Urethral or cervical infection with Chlamydia trachomatis coexisted with gonococcal infection in 14 (22%) of 63 patients and persisted in 7 of 10 patients treated with rosoxacin. Postgonococcal urethritis developed in 11 (34%) of 32 men who were monitored for 12 to 30 days. Sixty-four subjects (51%) developed transient dizziness, drowsiness, altered visual perceptions, or other symptoms suggestive of central nervous system dysfunction after treatment with rosoxacin, but these symptoms were not clearly dose related. Rosoxacin in doses of greater than or equal to 200 mg appears to be effective for single-dose treatment of uncomplicated gonorrhea, but further studies of its possible central nervous system toxicity are indicated.
 ...
PMID:Treatment of uncomplicated gonorrhea with rosoxacin. 679 24

The results of this open multicenter trial with 100 patients of both sexes show that a single 300-mg dose of rosoxacin (Win 35,213) was effective in achieving a 94% cure rate, both clinical and bacteriological, on the seventh day after treatment in patients with uncomplicated acute gonococcal infection. The cure rate in men was 94% (86/92) and in women 100% (8/8). All isolates of Neisseria gonorrhoeae were susceptible to rosoxacin, as determined by 5-micrograms sensitivity disks. Adverse effects were seen in 14 patients--13 men and one woman. Twelve patients reported dizziness, one drowsiness, and one visual changes. It is concluded that rosoxacin can be of great usefulness in the epidemiological control of acute gonococcal infection, because of the lack of in vitro resistance to it, its minimal adverse effects, the low dose requirements, and the effectiveness of a single dose. The drug does not appear to have any treponemicidal action.
 ...
PMID:Rosoxacin (Win 35,213) in the treatment of uncomplicated acute gonococcal infection. 709 83

Gatifloxacin is a novel extended-spectrum fluoroquinolone with improved gram-positive and anaerobe coverage compared with older agents such as ciprofloxacin. It has good activity (but is slightly less active than ciprofloxacin) against Enterobacteriaceae. Gatifloxacin is generally 2- to 4-fold more active than ciprofloxacin against staphylococci, streptococci and enterococci and 4- to 16-fold more active than ciprofloxacin against anaerobes, including Clostridium and Bacteroides spp. In comparative clinical trials that included patients with lower respiratory tract, urinary tract, skin and soft tissue or gonococcal infections, clinical cure rates of > or = 89% were achieved with oral gatifloxacin 400 mg/day for 7 to 14 days. Data from a subset of North American patients included in a multinational trial showed that oral gatifloxacin 400 mg/day produced a significantly higher clinical cure rate than cefuroxime axetil 250 mg twice daily (89 vs 77%; p = 0.01) in patients with acute exacerbations of chronic bronchitis. The clinical efficacy of gatifloxacin was similar to that of clarithromycin or levofloxacin or ceftriaxone (with or without erythromycin) in the treatment of patients with community-acquired pneumonia. Oral gatifloxacin 400 mg/day showed clinical and bacteriological efficacy similar to that of levofloxacin in patients with skin and soft tissue infections. In patients with urinary tract infections, clinical cure and bacterial eradication rates achieved with a single 400 g oral dose of gatifloxacin were similar to those produced with ciprofloxacin. In a pooled analysis of tolerability data from trials that included 3021 patients treated with oral gatifloxacin 400 mg/day, the most commonly reported adverse events were nausea (8%), diarrhoea (4%), headache (4%) and dizziness (3%). The drug was reported to be well tolerated. Gatifloxacin does not appear to cause phototoxic effects.
 ...
PMID:Gatifloxacin. 1055 38

Gonorrhea treatment has become a problem in most parts of the world and valid recommendations regarding treatment are an important control tool. In Central African Republic genital gonorrhea is one of the most common communicable diseases. In 1981 Penicillinase Producing Neisseria Gonorrhea (PPNG) was 1st isolated and, in spite of control measures, its prevalence reached 12% by the end of 1982. Effective and inexpensive treatment regimens are now needed as an alternative to the Procain Penicillin + Probenicid regimen currently in use. Since its introduction, many authors in industrialized countries have reported excellent results with Thiamphenicol (TAP) in the treatment of gonococal infections, particularly in the single dose oral treatment. Gonococcal infections caused by Penicillinase Producing Neisseria gonorrhea (PPNG) also responded favorably to the antibiotic. However, few careful studies were done in Africa. This study evaluates the efficacy of TAP compared with the standard regimen of Aqueous Procain Penicillin + Probenicid in the treatment of uncomplicated genital gonorrhea in men in Central African Republic. 380 such cases were used. Patients with coexisting genital ulcers and those treated with antimicrobics within the last 2 weeks were excluded. Gram stained smears were examined and a urethral swab was taken and cultured on a modified Thayer Martin medium. Blood specimens were collected for VDRL and TPHA tests. During a 3-month period 338 patients were treated with a positive pretreatment culture for N. gonorrhea. 242 (71.6%) presented at follow-up, with similar follow-up rates in both treatment groups (25 mg. Thiamphenicol and Aqueous Procain Penicillin G. + 1g. Probenicid). All failures but 1 in the APPG treatment group were due to PPNG infections. All of those cases were treated with Thiamphenicol regimen, 4 were cured and 6 lost for follow-up. Of 12 PPNG infections treated with Thiamphenicol, only 1 failed treatment and was cured with spectinomycin. Only few and mild side effects (diarrhea or dizziness) resulted from treatment. Thiamphenicol in single oral regimen is a low cost, effective therapy for uncomplicated gonococcal infection in males in the Central African Republic and may become potentially one of the recommended regimens if the prevalence of PPNG continues to increase.
 ...
PMID:Thiamphenicol in treatment of genital gonorrhoeae in Central African Republic. 1234 Jan 81

Alisma orientale (Sam.) Juzep. (Alismataceae) is a traditional and famous Chinese medicinal herb. Its rhizomes, which possess versatile bioactivities, are commonly used to treat oliguria, edema, gonorrhea with turbid urine, leukorrhea, diarrhea and dizziness. Approximately 120 compounds have been isolated from A. orientale. Terpenoids have been identified as A. orientale's characteristic constituents, which include protostane triterpenoids and guaiane sesquiterpenoids. The traditional medical uses of A. orientale in TCM have been evaluated in modern pharmacological studies, which have shown that A. orientale and its active constituents exhibit a wide range of bioactivities, such as diuretic, anti-urolithiatic, antinephritic, anti-atherosclerotic, immunomodulatory, and hepatoprotective activities. The medicinal potential of A. orientale makes it an ideal candidate for new drug development. Further studies are still required to identify its bioactive constituents, and elucidate the structure-activity relationship and detailed mechanisms of action. Additionally, the use of the other medicinal parts of A. orientale may reduce resource waste and afford novel secondary metabolites.
 ...
PMID:Alisma orientale: Ethnopharmacology, Phytochemistry and Pharmacology of an Important Traditional Chinese Medicine. 2708 Sep 39